Cosibelimab

Product Specifications

CAS Number

2216751-26-5

Target

PD-1/PD-L1

Related Pathways

Immunology/Inflammation|||Apoptosis|||Cell Cycle/Checkpoint

Bioactivity

Cosibelimab (CK-301; TG-1501) is a fully human, high-affinity monoclonal antibody that inhibits PD-L1 by preventing its interaction with PD-1. Featuring a functional Fc domain, this compound effectively induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), targeting and eliminating PD-L1+ cell lines, including lymphoma cells [1].